Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772035 | 0.94 | NPC1 (0.54) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL18794846 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL18794843 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL18794854 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL15656044 | 0.85 | MAPT (0.54) | ALDH1A1KMT2AMCOLN3MEN1MAPT | |
| SCHEMBL5065638 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL6926208 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL8882067 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KMT2AMCOLN3MEN1HTT | |
| SCHEMBL21291444 | 0.84 | HCRTR1 (0.51) | ALDH1A1KMT2AMCOLN3EPHX2CASP3 | |
| SCHEMBL29360904 | 0.84 | HCRTR1 (0.51) | ALDH1A1KMT2AMCOLN3EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-6225306-B1 | PYRROLO(1,2A)QUINOXALINES | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
| EP-0987266-A1 | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | ALDH1A1 4229/4885KMT2A 3707/4885MCOLN3 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.